Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
AssigneeScantibodies Laboratory, Inc.
InventorThomas L. Cantor
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism. One determines and monitors the level of parathyroid hormone agonist and parathyroid hormone antagonist in the renal patient. The parathyroid hormone suppressing therapeutic is administered to the patient so as to minimize the level of parathyroid hormone antagonist.
Claims42
A method for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism comprising:
- a) determining and monitoring the level of a parathyroid hormone (PTH) agonist in a renal patient having secondary hyperparathyroidism;
- b) determining and monitoring the level of a PTH antagonist in the patient;
- and
- c) administering a therapeutic to the patient that suppresses PTH agonist whereby the amount of therapeutic administered is adjusted such that PTH agonist levels are decreased and the level of PTH antagonist is minimized.
A method for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism comprising:
- a) obtaining a sample from a renal patient having secondary hyperparathyroidism;
- b) determining and monitoring the level of a parathyroid hormone (PTH) antagonist in the renal patient;
- and
- c) administering a therapeutic to the patient capable of suppressing a PTH agonist, whereby the amount of therapeutic administered is adjusted such that the level of PTH antagonist is minimized in the patient.
A kit useful for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism comprising:
- a) means for monitoring the level of parathyroid hormone (PTH) agonist in a renal patient having secondary hyperparathyroidism;
- b) means for monitoring the level of PTH antagonist in the patient;
- and
- c) means for administering a therapeutic to the patient that suppresses PTH agonist whereby the amount of therapeutic administered is adjusted such that PTH agonist levels are decreased and the level of PTH antagonist is minimized.
Dependencies are inferred from the claim text.